Table 3.

Disease-specific survival of lung cancer patients in relation to clinicopathologic characteristics and the MBL2 Y/X polymorphism^*

		Univariate analysis		Multivariable analysis
Variable	Category	RR of death (95% CI)	P†	RR of death (95% CI)	P†
White patients
Age	Continuous	1.00 (0.99 to 1.01)	.92	1.01 (1.00 to 1.02)	.19
Sex	Female vs male	0.88 (0.66 to 1.09)	.21	0.79 (0.60 to 1.04)	.09
Stage	Stages II–IV vs I	3.53 (2.70 to 4.61)	<.001	3.83 (2.89 to 5.07)	<.001
Smoking pack-years	Continuous	1.00 (0.99 to 1.00)	.30	1.00 (0.99 to 1.00)	.12
Y/X polymorphism	C/C + C/G vs G/G	0.66 (0.51 to 0.86)	.003	0.55 (0.42 to 0.73)	<.001
African American patients
Age	Continuous	1.00 (0.98 to 1.03)	.74	1.02 (0.99 to 1.04)	.14
Sex	Female vs male	0.82 (0.55 to 1.21)	.31	0.70 (0.46 to 1.07)	.10
Stage	Stages II–IV vs I	4.32 (2.74 to 6.80)	<.001	4.71 (2.87 to 7.75)	<.001
Smoking pack-years	Continuous	0.99 (0.99 to 1.00)	.15	1.00 (0.99 to 1.01)	.88
Y/X polymorphism	C/C + C/G vs G/G	1.19 (0.77 to 1.85)	.43	1.01 (0.63 to 1.60)	.98

^*RR = risk ratio; CI = confidence interval.

^†A Cox proportional hazards test was used. All statistical tests were two-sided.